Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

HealthDay News — Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) therapy, according to a study published online August 14 in ...

"Anyone who knows Dougie knows that he is an incredibly kind, caring and hardworking man who would do anything for his family" ...

China NMPA grants breakthrough therapy designation to Antengene’s ATG-022 to treat gastric/gastroesophageal junction adenocarcinoma: Shanghai Wednesday, August 20, 2025, 16:00 H ...

National registry study finds overall survival improved across the board after the introduction of immune checkpoint ...

Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

The Mural board of directors said that they have determined the acquisition and cash offer by XOMA is in the best interest of ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

Personalized vaccines are currently being investigated for the treatment of patients with kidney cancer; however, the ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody. Read why I rate CBIO stock as a ...